- Trials with a EudraCT protocol (127)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
127 result(s) found for: cholangiocarcinoma.
Displaying page 2 of 7.
| EudraCT Number: 2018-004004-19 | Sponsor Protocol Number: QBGJ398-301 | Start Date*: 2020-02-13 | |||||||||||
| Sponsor Name:QED Therapeutics, Inc. | |||||||||||||
| Full Title: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGF... | |||||||||||||
| Medical condition: Cholangiocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002888-10 | Sponsor Protocol Number: PCIA202/12 | Start Date*: 2012-12-06 | |||||||||||
| Sponsor Name:PCI Biotech AS | |||||||||||||
| Full Title: A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-induced Photochemical Internalisation (PCI) of Gemcitabine Followed by Gemcitabine/Cisplatin Chemoth... | |||||||||||||
| Medical condition: Inoperable advanced cholangiocarcinomas | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Prematurely Ended) FR (Completed) LT (Prematurely Ended) NO (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005078-70 | Sponsor Protocol Number: ACTICCA-1 | Start Date*: 2014-01-16 | ||||||||||||||||
| Sponsor Name:University Medical Center Hamburg-Eppendorf | ||||||||||||||||||
| Full Title: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) ... | ||||||||||||||||||
| Medical condition: Cholangiocarcinoma and gallbladder carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Completed) AT (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2016-003812-10 | Sponsor Protocol Number: PHP-ICC-203 | Start Date*: 2017-08-29 | |||||||||||
| Sponsor Name:Delcath Systems Inc. | |||||||||||||
| Full Title: A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Stand... | |||||||||||||
| Medical condition: Intrahepatic cholangiocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-020188-19 | Sponsor Protocol Number: 1003 | Start Date*: 2010-09-24 | |||||||||||
| Sponsor Name:Oncology Department | |||||||||||||
| Full Title: Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine and in patients with a KRAS-wild type tumour in combination with cetuximab in... | |||||||||||||
| Medical condition: Patient with non-resectable liver metastases from cholangiocarcinoma. A phase II trial. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-004688-30 | Sponsor Protocol Number: D933AC00001 | Start Date*: 2019-07-17 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitab... | |||||||||||||
| Medical condition: First-line patients with advanced biliary tract cancers (BTC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-002446-39 | Sponsor Protocol Number: CUV025 | Start Date*: 2008-10-16 | ||||||||||||||||
| Sponsor Name:Clinuvel Pharmaceuticals Limited | ||||||||||||||||||
| Full Title: A Phase II, Multicentre, Double-blind, Placebo Controlled, Pilot Study to Evaluate the Safety and Efficacy of CUV1647 Administered as A Subcutaneous Bioresorbable 16mg Implant in Patients Undergoin... | ||||||||||||||||||
| Medical condition: Barrett's Oesohagus Cholangiocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2014-004981-52 | Sponsor Protocol Number: GEMNABCCC-001 | Start Date*: 2016-09-28 | |||||||||||
| Sponsor Name:University Hospital Essen | |||||||||||||
| Full Title: Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy – a pilot study The NACHO trial (GEMNABCCC-001) | |||||||||||||
| Medical condition: unresecable, metastatic or recurrent cholangiocarcinoma (intrahepatic cholangiocellular carcinoma, bile duct cancer, gall bladder carcinoma) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005626-30 | Sponsor Protocol Number: REACHIN | Start Date*: 2014-01-23 |
| Sponsor Name:CUB Erasme Hospital | ||
| Full Title: Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (non resectable) and metastatic cholangiocarcinoma: a randomized double-blinded phase II trial. | ||
| Medical condition: Locally advanced (non resectable) and metastatic histologically proven intra-hepatic or hilum cholangiocarcinoma + histologically proven metastatic extra-hepatic cholangiocarcinoma (common bile duc... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004826-27 | Sponsor Protocol Number: GI1863 | Start Date*: 2019-04-11 | |||||||||||||||||||||||||||||||
| Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital | |||||||||||||||||||||||||||||||||
| Full Title: A Single Center, Randomized, Phase II Study of the combination of Cisplatin and Gemcitabine with or without Tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advance... | |||||||||||||||||||||||||||||||||
| Medical condition: First-line treatment in patients with locally advanced or metastatic biliary tract cancer, inoperable due to extension of the disease. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-020480-21 | Sponsor Protocol Number: pro-duct001 | Start Date*: 2010-11-18 |
| Sponsor Name:Universitätsmedizin Charite | ||
| Full Title: Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer | ||
| Medical condition: proximal bile duct cancer | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-001575-16 | Sponsor Protocol Number: 2017-02-32-005 | Start Date*: 2021-11-29 | |||||||||||
| Sponsor Name:Centre Régional de lutte contre le Cancer Eugène Marquis | |||||||||||||
| Full Title: A multicenter open-label randomized controlled prospective phase II study evaluating the efficacy of Selective Internal Radiation Therapy (Yttrium-90 glass microspheres) combined with Capecitabine ... | |||||||||||||
| Medical condition: Patients having operable intrahepatic cholangiocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003759-14 | Sponsor Protocol Number: GO42661 | Start Date*: 2021-01-21 | ||||||||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | ||||||||||||||||||
| Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIAR... | ||||||||||||||||||
| Medical condition: Biliary tract cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: PL (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2007-005796-34 | Sponsor Protocol Number: CC-GEMSO-2007 | Start Date*: 2008-03-19 | |||||||||||
| Sponsor Name:Universität Mainz, I. Medizinische Klinik und Poliklinik | |||||||||||||
| Full Title: A randomized, double-blind, multicenter phase II trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemo-naive advanced or metastatic adenocarcinoma of the bili... | |||||||||||||
| Medical condition: Patients with Adenocarcinoma of the gallbladder or intrahepatic bile ducts or histologically proven hepatic metastases of an earlier resected and histologically proven biliary tract cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002382-30 | Sponsor Protocol Number: RDD677 | Start Date*: 2015-03-13 | |||||||||||||||||||||
| Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | |||||||||||||||||||||||
| Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with resectable proximal biliary tract cancer: | |||||||||||||||||||||||
| Medical condition: Resectable Biliary Tract Carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2014-001585-98 | Sponsor Protocol Number: PHP-HCC-202 | Start Date*: 2014-06-27 | ||||||||||||||||
| Sponsor Name:Delcath Systems, Inc | ||||||||||||||||||
| Full Title: An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan/HDS Treatment in Patients with Unresectable Hepatocellular Carcinoma or Intra hepatic Cholangiocarcinoma. | ||||||||||||||||||
| Medical condition: unresectable hepatocellular carcinoma (HCC) confined to the liver and Intra hepatic Cholangiocarcinoma confined to the liver. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2016-002467-34 | Sponsor Protocol Number: AIO-YMO/HEP-0315 | Start Date*: 2017-07-19 | |||||||||||||||||||||||||||||||
| Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||||||||||||
| Full Title: Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial | |||||||||||||||||||||||||||||||||
| Medical condition: Locally advanced or metastatic, non resectable, adenocarcinoma of the biliary tract including intrahepatic and extrahepatic bile duct | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-004013-41 | Sponsor Protocol Number: NL70452.078.19 | Start Date*: 2019-11-27 |
| Sponsor Name:Erasmus MC | ||
| Full Title: Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma | ||
| Medical condition: Unresectable intrahepatic cholangiocarcinoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-001867-29 | Sponsor Protocol Number: 1081HV | Start Date*: 2022-11-02 |
| Sponsor Name:Amsterdam UMC | ||
| Full Title: [68Ga]Ga-FAPI-46 positron emission tomography in pancreaticobiliary cancers: a pharmacokinetics, repeatability and diagnostic accuracy study. | ||
| Medical condition: Pancreatic carcinoma and cholangiocarcinoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-004535-24 | Sponsor Protocol Number: RLY-4008-101 | Start Date*: 2021-07-07 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Relay Therapeutics, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A First-in-Human Study of Highly Selective FGFR2 inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and other Advanced Solid Tumors | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Unresectable or metastatic cholangiocarcinoma (CCA), other advanced solid tumors with an FGFR2-alteration or other potential FGFR2-dependent tumors | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: SE (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.